Analysts have suggested it could disrupt a market currently dominated by Factor VIII products from Baxalta ... appear to affect the activity of the drug. Roche is preparing to initiate a phase ...

The European Medicines Agency has approved Roche's rare arthritis drug, RoACTEMRA, for use in Europe. This approval comes only a month after EMA's Committee for Medicinal Products for Human Use ...

Roche has signed an agreement to acquire Poseida Therapeutics in a $1.5bn deal. The transaction includes Poseida's clinical ...

Roche has announced a definitive agreement to acquire Poseida Therapeutics, a clinical-stage biopharmaceutical company ...

The Financial Times report added that the drug is expected to be a game ... Analysts estimate that Roche’s weight-loss products will only generate around $4 billion in sales by 2032, a far ...

BERLIN, Nov 26 (Reuters) - A Roche study into using a combination of tiragolumab and tecentriq to treat a form of lung cancer in a phase III trial did not achieve the desired success, the Swiss ...

Roche RHHBY announced that it will acquire clinical-stage biopharmaceutical company Poseida Therapeutics, Inc. PSTX for $9 ...

On Tuesday, Roche said that much-anticipated results from a Phase 3 trial called SKYSCRAPER-01 showed the drug, tiragolumab, did not help people with advanced or metastatic lung cancer live longer.

In return, Roche will gain worldwide rights to develop and market certain products identified prior ... to $1 billion in milestone payments if the drugs reach the market. Store-operated Ca 2 ...

In an exciting development for shareholders and the biotechnology industry alike, Poseida Therapeutics, Inc. (Nasdaq: PSTX) has seen its stock price surge by an impressive 221.68%, reaching $9.20 in ...

Roche inks agreement to acquire clinical-stage biopharma company, Poseida Therapeutics: Basel Wednesday, November 27, 2024, 09:00 Hrs [IST] Roche announced that it has entered int ...